Medifast, Inc. — FY2021 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. Medifast sells weight-management and wellness products primarily through OPTAVIA, a direct-to-consumer business supported by independent Coaches. Product sales generated approximately 98% of revenue; OPTAVIA represented approximately 99.9% of revenue in 2021. The company had 59,800 active earning Coaches at year-end.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $1,526.1 million | $934.8 million | +63.2% |
| Gross profit / margin | $1,127.6 million / 73.9% | $697.8 million / 74.6% | Profit +61.6%; margin -0.7 percentage points |
| Operating income / margin | $216.2 million / 14.2% | $134.2 million / 14.4% | Income +61.2%; margin -0.2 percentage points |
| Net income | $164.0 million | $102.9 million | +59.5% |
| Diluted EPS | $13.89 | $8.68 | +60.0% |
| Operating cash flow | $94.5 million | $145.2 million | Down $50.7 million |
- Growth drivers and costs: Revenue growth reflected more active Coaches and higher productivity per Coach. Q4 average revenue per active earning Coach was $6,321, up 6.6% year over year. Coach compensation rose $272.1 million to $667.2 million. Raw ingredient, freight, and labor inflation, plus greater use of co-manufacturers, pressured gross margin.
- Cash, working capital, and investment: Cash and cash equivalents were $104.2 million at year-end, down from $163.7 million; cash plus investment securities totaled $109.5 million, versus $174.5 million. Working capital was $137.0 million, compared with $123.0 million. Inventory rose to $180.0 million from $53.4 million as the company built stock to support demand. Capital expenditures were $34.2 million; cash used in investing activities was $29.1 million.
- Capital returns: The company paid $63.9 million in dividends and repurchased $56.0 million of stock in 2021. Dividends declared were $5.68 per share for the year. A $1.42-per-share quarterly dividend declared in December was paid February 8, 2022.
- Debt and obligations: No borrowings were outstanding under the $125 million revolving credit facility at year-end; it matures in April 2026 and includes an option for up to $100 million of additional commitments, subject to conditions. Contractual obligations totaled $233.3 million, including $198.9 million of unconditional purchase obligations.
Material changes and management commentary
- The active earning Coach count increased 35.3%, from 44,200 to 59,800. Revenue growth was 63.2%, while operating income grew 61.2%.
- Gross margin declined to 73.9% from 74.6%, primarily due to inflation in ingredients, freight, and labor. The company raised product prices by 3.5% in December 2021.
- Operating cash flow decreased despite higher earnings, mainly reflecting increased inventory purchases and changes in operating assets and liabilities.
- The Medifast Direct channel and Medifast-branded product line were sunset during the second quarter of 2021 as the company focused on OPTAVIA.
- Management expects the Coach-based model and continued investment in OPTAVIA to support growth, but provided no specific financial guidance or quantified forecast in the supplied filing text. The company stated it expects to fund future cash needs through operating cash flow and financing activities and intends to continue dividends, without guaranteeing future payments.
Risks, contingencies, and unusual items
- Key risks include regulatory scrutiny of direct selling and Coach earnings, health or product claims, and advertising and testimonials; dependence on retaining and growing the Coach network; competition and changing consumer preferences; and the ability to manage rapid growth.
- Supply-chain disruption, reliance on third-party manufacturers and distributors, inflation, and dependence on a single company manufacturing facility could affect product availability, costs, and results. Despite these risks, the company reported no meaningful supply-chain disruption to date during the pandemic.
- COVID-19, economic conditions and discretionary consumer spending, international expansion, cybersecurity and privacy, product liability, and the company’s ability to sustain dividends are additional risks identified by management.
- The company reported ordinary-course litigation and did not believe it would have a material adverse effect, while noting outcomes cannot be predicted with certainty. No material uncertain tax positions were reported.
- Independent auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective at year-end.
Important facts for investors to verify
- Whether Coach growth, Coach retention, and revenue per Coach remain strong, and how much growth depends on expanding the network versus higher client spending.
- Whether the large inventory build supports demand without leading to obsolescence, returns, or further working-capital pressure.
- Whether price increases and cost management can offset continued ingredient, freight, labor, and co-manufacturing cost inflation.
- Whether operating cash flow recovers as inventory and other working-capital needs normalize, given continued capital spending and shareholder distributions.
- Whether regulatory or legal developments affecting direct selling, Coach claims, advertising, or product safety require changes to the business or compensation model.
- The company’s future dividend and repurchase decisions, and compliance with credit-facility covenants if borrowings are drawn.